7Baggers

BioLife Solutions Quarterly Balance Sheets Chart

Quarterly
 | 
Annual
 
 Goodwill  
 Cash and Cash Eq  
 Account Payables  
 Inventory  
20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20240630 20240930 20241231 20250331 032.1164.2196.32128.42160.53192.64224.74Milllion

BioLife Solutions Quarterly Balance Sheets Table

Quarterly
 | 
Annual
 
Unit: USD2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-09-30 2008-06-30 2008-03-31 
                                                                      
  assets                                                                    
  current assets:                                                                    
  cash and cash equivalents66,945,000 95,386,000 23,977,000 22,014,000 29,694,000 35,407,000 19,235,000 21,400,000 19,105,000 19,442,000 27,036,000 24,001,000 59,463,000 69,860,000 75,098,000 76,246,000 89,012,000 90,403,000 93,984,000 29,879,000 6,400,000 6,448,000 21,205,000 19,617,000 31,824,000 30,657,000 32,380,674 14,166,604 7,032,513 6,663,318 2,830,541 2,314,633 2,289,926 1,405,826 1,368,583 1,318,469 1,662,431 2,173,258 2,351,540 3,896,405 2,971,840 2,538,758 3,275,057 5,902,228 12,839,600 156,273 79,287 76,205 61,523 196,478 7,529 155,354 70,524 16,864 20,117 36,145 35,097 3,211 298 67,881 2,292 139,151 95,814 86,403 428,196 85,070 87,715 136,182 
  available-for-sale securities, current portion21,635,000 9,198,000 10,211,000 12,120,000 15,579,000 16,288,000 21,794,000 24,858,000 35,780,000 43,260,000 34,583,000 22,546,000                                                         
  accounts receivable, trade, net of allowance for credit losses of 117 and 153 as of march 31, 2025 and december 31, 2024, respectively9,167,000                                                                    
  inventories27,566,000 29,013,000 32,179,000 32,496,000 43,414,000 43,456,000 43,354,000 39,177,000 41,329,000 34,904,000 33,747,000 33,335,000 30,200,000 28,345,000 29,696,000 25,866,000 11,666,000 11,602,000 11,037,000 10,890,000 10,829,000 10,972,000 5,694,000 5,306,000 4,060,000 3,509,000 2,910,927 2,121,881 1,836,666 1,846,746 1,861,058 1,769,070 1,812,172 1,757,784 1,903,759 1,910,729 2,018,255 1,834,635 1,783,383 1,321,257 1,242,787 965,224 717,624 678,156 297,105 420,924 409,195 593,138 676,438 656,397 849,211 916,810 763,967 505,956 475,126 509,572 447,306 410,486 499,450 532,431 436,529 358,219 237,651 379,230 453,011 587,726 121,655 97,047 
  prepaid expenses and other current assets5,816,000 5,996,000 4,914,000 3,475,000 4,408,000 6,765,000 7,854,000 7,985,000 6,201,000 6,879,000 8,041,000 6,890,000 4,757,000 4,427,000 5,426,000 4,156,000 5,143,000 4,648,000 1,668,000 1,134,000 1,016,000 1,348,000 855,000 384,000 346,000 353,000 298,005 352,507 330,904 399,502 320,318 422,408 419,124 270,814 381,883 402,342 435,592 384,414 453,789 313,412 289,018 360,521 320,761 312,148 202,784 291,745 140,077 165,292 201,801 174,731 122,914 76,657 68,299 90,444 90,903 66,530 77,782 62,377 69,837 73,267 85,747 79,635 138,814 44,655 123,816    
  total current assets131,129,000 148,761,000 89,383,000 88,200,000 111,700,000 120,604,000 116,824,000 120,311,000 132,789,000 138,452,000 135,874,000 118,057,000 118,701,000 125,859,000 130,505,000 127,414,000 116,543,000 114,712,000 127,784,000 46,254,000 26,450,000 24,113,000 32,067,000 29,139,000 39,157,000 37,564,000 38,288,948 18,807,407 10,243,898 9,930,881 6,367,032 5,679,147 5,581,995 4,628,070 4,965,231 4,915,555 5,306,538 6,972,937 8,283,091 9,296,889 10,961,142 12,165,762 12,832,803 13,471,381 14,665,053 1,878,258 1,655,417 1,815,609 1,915,919 1,627,759 1,777,597 1,508,011 1,374,606 1,160,407 1,044,823 1,007,571 916,886 814,973 886,643 958,820 883,340 892,370 841,608 709,480 1,329,890 1,168,198 744,908 743,048 
  assets held for rent5,690,000 6,103,000 10,822,000 11,094,000 6,904,000 7,713,000 7,209,000 9,417,000 9,005,000 9,064,000 9,357,000 9,083,000 9,823,000 9,809,000 10,086,000 8,492,000 6,503,000 4,705,000 5,131,000 4,958,000 4,875,000 3,922,000 2,976,000                                              
  property and equipment6,605,000 6,084,000 17,709,000 17,256,000 21,042,000 21,077,000 20,998,000 25,565,000 26,100,000 23,638,000 21,737,000 19,117,000 18,259,000 17,657,000 17,462,000 16,450,000 11,231,000 10,120,000 5,300,000 5,347,000 5,407,000 5,572,000                                               
  operating lease right-of-use assets10,128,000 10,674,000 14,402,000 10,400,000 10,779,000 11,446,000 12,651,000 14,935,000 15,592,000 15,292,000 15,832,000 17,306,000 18,161,000 18,705,000 17,157,000 17,400,000 10,524,000 9,675,000 585,000 740,000 892,000 1,040,000 1,177,000 1,079,000 1,196,000                                            
  long-term deposits and other assets378,000 379,000 271,000 241,000 245,000 273,000 316,000 316,000 284,000 281,000 256,000 323,000 265,000 325,000 386,000 452,000 356,000 230,000 35,000 36,000 36,000 50,000                                               
  available-for-sale securities, long-term19,055,000  4,884,000 2,688,000 822,000  1,156,000 1,839,000 2,019,000  490,000 489,000                                                         
  equity investments995,000 995,000 995,000 995,000 5,069,000 5,069,000 5,069,000 5,069,000 5,069,000 5,069,000 5,069,000 4,372,000                                                         
  intangible assets8,857,000 9,559,000 18,415,000 19,325,000 20,235,000 21,149,000 22,064,000 29,177,000 30,629,000 32,088,000 74,013,000 76,524,000 149,286,000 152,149,000 155,011,000 148,714,000 30,116,000 31,049,000 19,882,000 20,588,000 21,294,000 21,982,000 16,485,000 4,446,000                                             
  goodwill212,304,000 212,304,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 224,741,000 223,936,000 195,664,000 58,449,000 58,449,000 33,506,000 33,506,000 33,506,000 33,637,000 28,351,000 9,524,000                                             
  total assets395,141,000 399,487,000 381,652,000 374,976,000 401,602,000 412,714,000 411,152,000 433,177,000 446,470,000 450,229,000 487,679,000 470,379,000 544,012,000 554,057,000 559,391,000 520,969,000 240,024,000 234,829,000 195,887,000 113,970,000 94,987,000 92,816,000 84,228,000 51,742,000 48,073,000 45,467,000 46,448,976 21,787,020 12,293,079 12,143,203 8,881,486 8,481,722 8,598,774 7,926,614 10,766,378 10,550,454 10,775,853 12,369,622 13,225,577 13,870,187 15,160,420 16,072,918 14,254,063 14,806,565 15,981,534 3,353,342 3,207,024 3,437,081 3,419,277 3,169,829 3,417,833 3,068,907 1,869,170 1,662,017 1,564,376 1,471,981 1,386,251 1,309,059 1,293,655 1,384,760 1,328,018 1,333,958 1,310,008 1,203,450 1,745,300 1,302,592 850,725 854,527 
  liabilities and shareholders’ equity                                                                    
  current liabilities:                                                                    
  accounts payable3,297,000 3,573,000 3,838,000 4,213,000 4,984,000 6,940,000 11,980,000 10,686,000 15,525,000 15,367,000 13,140,000 11,537,000 11,711,000 14,945,000 14,296,000 9,847,000 4,276,000 3,672,000 2,355,000 3,077,000 3,522,000 3,119,000 1,570,000 876,000 1,264,000 720,000 1,089,553 842,941 586,334 690,702 420,387 531,919 638,014 710,719 1,085,723 864,452 772,870 1,029,373 978,279 640,271 900,348 474,662 168,838 170,106 707,983 867,070 840,498 1,041,717 1,053,911 862,492 1,064,283 531,616 534,001 403,103 310,442 347,063 276,515 117,068 228,898 343,280 268,227 192,834 211,825 400,277 586,150 654,625 362,567 284,014 
  accrued expenses and other current liabilities8,213,000 12,451,000 8,449,000 8,128,000 8,863,000 11,932,000 8,568,000 10,114,000 10,701,000 9,782,000 7,778,000 7,187,000 6,966,000 7,142,000 12,057,000 9,911,000 8,146,000 5,369,000 3,364,000 2,606,000 3,080,000 3,369,000 642,000 204,000 142,000 91,000 162,981 172,879 202,779 200,548 170,419 63,619 69,327 116,399 50,614 80,037 113,340 146,438 150,980 62,741 160,898 121,869 90,475 10,440 30,044 146,626 52,532 51,820 19,981 8,495 149,609 126,224 58,207 69,582   81,420 108,015           
  sales taxes payable3,929,000 4,256,000 4,351,000 4,860,000 5,395,000 5,442,000 5,469,000 4,989,000 4,585,000 4,151,000                                                           
  lease liabilities, operating, current portion1,835,000 1,511,000 2,788,000 2,504,000 2,645,000 2,797,000 2,906,000 2,915,000 2,906,000 2,860,000 2,769,000 2,733,000 2,795,000 2,758,000 2,648,000 2,223,000 1,455,000 1,107,000 729,000 844,000 826,000 804,000                                               
  debt, current portion10,449,000 10,943,000 12,231,000 10,614,000 8,619,000 6,833,000 5,034,000 1,935,000 1,250,000 1,814,000 2,067,000 1,363,000 557,000 862,000 1,771,000 2,924,000                                                     
  total current liabilities27,723,000 32,734,000 32,166,000 30,819,000 38,658,000 42,178,000 42,622,000 39,587,000 47,319,000 44,582,000 36,948,000 33,298,000 35,040,000 40,381,000 35,793,000 31,275,000 16,381,000 15,573,000 8,362,000 7,490,000 25,460,000 7,669,000 4,944,000 3,093,000 2,701,000 1,939,000 2,095,365 1,663,728 1,311,577 1,512,898 1,089,343 1,045,091 1,085,580 1,133,163 3,464,488 2,263,541 1,479,984 1,725,793 1,631,901 1,160,156 1,464,385 1,261,776 833,014 613,004 1,063,655 1,628,140 1,228,905 1,423,192 1,473,479 1,365,338 1,468,094 1,021,142 687,813 579,248 516,148 502,774 463,845 340,702 10,377,601 10,062,273 9,506,001 356,673 8,654,441 8,098,243 7,658,186 1,030,087 507,517 441,305 
  lease liabilities, operating, long-term12,165,000 12,723,000 15,189,000 11,075,000 12,579,000 13,205,000 13,677,000 14,388,000 15,114,000 14,962,000 14,474,000 15,205,000 15,917,000 16,466,000 15,047,000 15,474,000 9,299,000 8,757,000 26,000 116,000 332,000 550,000                                               
  debt, long-term2,499,000 4,997,000 7,823,000 10,451,000 15,681,000 18,311,000 20,937,000 23,572,000 23,692,000 23,793,000 24,207,000 6,188,000 6,313,000 6,353,000 6,122,000 5,019,000                                                     
  deferred tax liabilities130,000 124,000 100,000 193,000 193,000 188,000 286,000 263,000 263,000 250,000 389,000 1,149,000 4,888,000 5,487,000 7,269,000 10,973,000                                                     
  total liabilities42,517,000 50,578,000 56,191,000 53,534,000 68,197,000 75,051,000 79,135,000 81,049,000 88,363,000 86,041,000 79,430,000 58,066,000 65,492,000 73,920,000 70,132,000 68,688,000 31,247,000 29,583,000 9,036,000 8,127,000 27,278,000 49,362,000 7,266,000 5,476,000 3,707,000 2,319,000 2,519,333 2,131,920 1,821,615 2,050,617 1,666,943 1,660,764 5,795,088 4,760,474 4,178,239 3,004,429 2,246,028 2,510,251 2,441,176 1,993,132 2,312,426 2,136,601 1,586,856 1,408,149 1,904,385 16,624,863 16,066,394 16,099,775 15,819,636 15,655,852 15,453,615 14,809,595 13,299,845 12,842,503 12,385,875 11,955,824 11,486,656 10,857,971 10,511,768 10,201,440 9,650,168 9,160,940 8,808,608 8,165,743 7,728,186 5,686,992 4,589,043 3,944,049 
  commitments and contingencies                                                                    
  shareholders’ equity:                                                                    
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of march 31, 2025 and december 31, 2024                                                                    
  common stock48,000    46,000 45,000 44,000 43,000 43,000 43,000 43,000 43,000 42,000 42,000 41,000 41,000 34,000 33,000 32,000 26,000 21,000 21,000 20,000 19,000 19,000 19,000 18,237 16,107 14,145 14,021 13,333 13,210 13,017 12,864 12,769 12,607 12,508 12,447 12,172 12,154 12,107 12,084 12,053 12,027 11,941 5,030 70,415 70,036 70,036 69,680 69,680 69,680 69,680 69,680   69,680 69,680    69,680 69,640 69,640 69,640  69,640  
  additional paid-in capital688,092,000    659,063,000 651,305,000 632,593,000 623,412,000 619,227,000 611,739,000 604,060,000 597,810,000 591,002,000 585,397,000 579,929,000 542,864,000 307,246,000 302,598,000 282,076,000 199,941,000 145,432,000 143,485,000 137,392,000 116,013,000 114,951,000 114,160,000 115,775,040 92,653,721 84,517,966 84,036,444 80,494,953 79,676,523 74,891,236 74,355,645 74,027,593 73,719,666 72,983,853 72,823,398 72,347,856 72,149,598 71,969,748 71,911,328 71,862,179 71,727,860 71,519,816 43,618,686 43,480,884 43,368,029 43,347,858 43,255,374 43,194,027 43,136,893 42,948,013 42,901,325 42,849,142 42,708,130 42,654,888 42,576,260 42,436,420 42,393,781 42,351,167 42,314,560 42,287,747 42,261,432 42,229,912 42,184,559 42,167,816 42,154,117 
  accumulated other comprehensive loss, net of taxes33,000    -566,000 -345,000 -660,000 -499,000 -534,000 -679,000 -1,257,000 -900,000 -438,000 -282,000                                                       
  accumulated deficit-335,549,000    -325,138,000 -313,342,000 -299,960,000 -270,828,000 -260,629,000 -246,915,000 -194,597,000 -184,640,000 -112,086,000 -105,020,000 -90,548,000 -90,627,000 -98,503,000 -97,385,000 -95,257,000 -94,124,000 -77,744,000 -100,052,000 -60,450,000 -69,766,000 -70,604,000 -71,031,000 -71,863,637 -73,014,731 -74,060,651 -73,957,883 -73,293,747 -72,868,779 -72,100,567 -71,202,369 -67,878,835 -66,909,834 -65,553,751 -64,326,923 -63,207,536 -62,138,848 -61,144,469 -60,112,987 -59,200,419 -58,337,964 -57,454,608 -56,895,237  -56,100,759 -55,818,253 -55,811,077 -55,299,489 -54,947,261 -54,448,368 -54,151,491 -53,740,321 -53,261,653 -52,824,973 -52,194,852 -51,724,213 -51,280,141 -50,742,997 -50,211,222 -49,855,987 -49,293,365 -48,282,438 -46,638,599 -45,975,774 -45,313,279 
  total shareholders’ equity352,624,000    333,405,000 337,663,000 332,017,000 352,128,000 358,107,000 364,188,000 408,249,000 412,313,000 478,520,000 480,137,000 489,259,000 452,281,000 208,777,000 205,246,000 186,851,000 105,843,000 67,709,000 43,454,000 76,962,000 46,266,000 44,366,000 43,148,000 43,929,643 19,655,100 10,471,464  7,214,543 6,820,958 2,803,686   7,546,025 8,529,825                                
  total liabilities and shareholders’ equity395,141,000    401,602,000 412,714,000 411,152,000 433,177,000 446,470,000 450,229,000 487,679,000 470,379,000 544,012,000 554,057,000 559,391,000 520,969,000 240,024,000 234,829,000 195,887,000 113,970,000 94,987,000 92,816,000 84,228,000 51,742,000 48,073,000 45,467,000 46,448,976 21,787,020 12,293,079 12,143,203 8,881,486 8,481,722 8,598,774   10,550,454 10,775,853                                
  accounts receivable, trade, net of allowance for credit losses of 153 and 1,603 as of december 31, 2024 and december 31, 2023, respectively 9,168,000                                                                   
  current assets, discontinued operations                                                                    
  available-for-sale securities, long term 4,628,000    548,000    1,332,000                                                           
  long-term assets, discontinued operations                                                                    
  current liabilities, discontinued operations                                                                    
  long-term liabilities, discontinued operations                                                                    
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of december 31, 2024 and december 31, 2023                                                                    
  restricted cash  184,000 31,000 31,000 31,000 31,000 31,000 31,000 31,000 31,000 28,000 10,000 10,000 53,000 53,000 53,000 53,000                                                   
  accounts receivable, trade, net of allowance for credit losses of 955 and 1,707 as of september 30, 2024 and december 31, 2023, respectively  17,918,000                                                                  
  financing lease right-of-use assets  30,000 36,000 65,000 94,000 124,000 1,807,000 242,000 272,000 310,000 367,000 404,000 440,000 476,000 511,000 430,000 17,000                                                   
  warranty liability  186,000 183,000 7,800,000 7,858,000 8,215,000 8,436,000 8,895,000 8,312,000 8,367,000 8,722,000 9,176,000 9,398,000                                                       
  lease liabilities, financing, current portion  323,000 317,000 352,000 376,000 398,000 426,000 161,000 158,000 156,000 153,000 151,000 149,000 146,000 144,000 114,000 8,000                                                   
  lease liabilities, financing, long-term  913,000 996,000 1,086,000 1,169,000 1,250,000 1,330,000 95,000 126,000 166,000 213,000 253,000 291,000 329,000 367,000 316,000 12,000                                                   
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of september 30, 2024 and december 31, 2023                                                                    
  accounts receivable, trade, net of allowance for credit losses of 1,061 and 1,710 as of june 30, 2024 and december 31, 2023, respectively   18,064,000                                                                 
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of june 30, 2024 and december 31, 2023                                                                    
  accounts receivable, trade, net of allowance for credit losses of 1,745 and 1,710 as of march 31, 2024 and december 31, 2023, respectively    18,574,000                                                                
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of march 31, 2024 and december 31, 2023                                                                    
  accounts receivable, trade, net of allowance for credit losses of 1,710 and 739 as of december 31, 2023 and december 31, 2022, respectively     18,657,000                                                               
  contingent consideration, current portion      52,000 86,000 3,296,000 2,138,000 2,671,000 1,603,000 3,684,000 5,127,000 2,714,000 2,854,000 2,390,000 2,637,000   365,000 377,000                                               
  contingent consideration, long-term      363,000 1,909,000 1,880,000 2,318,000 3,191,000 1,912,000 3,008,000 4,900,000 5,524,000 5,524,000 4,271,000 4,515,000 386,000 388,000 1,486,000                                                
  other long-term liabilities         10,000 55,000 101,000 73,000 42,000 48,000 56,000 980,000 726,000 262,000 133,000  4,000 3,000 7,000 13,000 31,000 37,855 45,364 52,520 45,512 51,235 56,141                                     
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of december 31, 2023 and december 31, 2022                                                                    
  accounts receivable, trade, net of allowance for credit losses of 1,244 and 739 as of september 30, 2023 and december 31, 2022, respectively      24,556,000                                                              
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of september 30, 2023 and december 31, 2022                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 1,265 and 739 as of june 30, 2023 and december 31, 2022, respectively       26,860,000                                                             
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of june 30, 2023 and december 31, 2022                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 956 and 739 as of march 31, 2023 and december 31, 2022, respectively        30,343,000                                                            
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of march 31, 2023 and december 31, 2022                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 739 and 275 as of december 31, 2022 and december 31, 2021, respectively         33,936,000                                                           
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of december 31, 2022 and december 31, 2021                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 496 and 275 as of september 30, 2022 and december 31, 2021, respectively          32,436,000                                                          
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of september 30, 2022 and december 31, 2021                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 458 and 275 as of june 30, 2022 and december 31, 2021, respectively           31,257,000                                                         
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of june 30, 2022 and december 31, 2021                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 275 and 275 as of march 31, 2022 and december 31, 2021, respectively            24,271,000                                                        
  investments            4,372,000 4,372,000 4,372,000 5,872,000 5,872,000 5,872,000 3,610,000 2,500,000 2,500,000 2,500,000 1,000,000                                              
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of march 31, 2022 and december 31, 2021                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 275 and 85 as of december 31, 2021 and december 31, 2020, respectively             23,217,000                                                       
  warrant liability                    17,667,000 39,602,000                                               
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of december 31, 2021 and december 31, 2020                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 287 and 85 as of september 30, 2021 and december 31, 2020, respectively              20,232,000                                                      
  line of credit              2,161,000 3,372,000                                                     
  warrant liability, current portion                 2,780,000 1,914,000 963,000                                                 
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of september 30, 2021 and december 31, 2020                                                                    
  accumulated other comprehensive loss              -163,000                       -451 -601 -1,390 -949 -6,448                           
  current assets                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 107 and 85 as of june 30, 2021 and december 31, 2020, respectively               21,093,000                                                     
  current liabilities                                                                    
  shareholders’ equity                                                                    
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively                                                                    
  accumulated other comprehensive income               3,000                            -3,507                         
  accounts receivable, trade, net of allowance for doubtful accounts of 80 and 85 at march 31, 2021 and december 31, 2020, respectively                10,669,000                                                    
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding at march 31, 2021and december 31, 2020, respectively                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 85 and 68 at december 31, 2020 and 2019, respectively                 8,006,000                                                   
  warrant liability, long-term                                                                    
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding at december 31, 2020 and 2019, respectively                                                                    
  restricted cash in escrow                  15,000,000                                                  
  accounts receivable, trade                  6,095,000 4,351,000 8,205,000                                                
  accrued interest receivable                  54,000 41,000 27,000                                                
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively                                                                    
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively                                                                    
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 68 and 0 at december 31, 2019 and 2018, respectively                     5,345,000                                               
  equity method investment in savsu                                                                    
  contingent consideration, long term                     1,537,000                                               
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 shares issued and outstanding at december 31, 2019 and 2018                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 68 and 0 at september 30, 2019 and december 31, 2018, respectively                      4,313,000                                              
  leasehold improvements                      1,599,000 1,284,000 1,284,000 1,284,000 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,284,491 1,121,362 1,121,362 1,121,362 1,121,362 1,121,362 1,121,362 941,925 919,035 943,878 864,361 3,936         202,270 202,270 202,270     
  furniture and computer equipment                      588,000 577,000 704,000 706,000 705,948 693,399 692,270 682,466 681,096 681,096 667,213 650,912 677,734 652,941 584,603 557,666 535,768 514,056 500,313 476,788 325,691 334,159 309,626 300,581 300,143 296,832 294,930 288,725 286,280 245,503 187,147 177,013 174,166 174,166 172,906 170,256 166,243 166,243 163,123 164,964 164,964 164,748 120,693 105,418 96,462 85,387 
  manufacturing and other equipment                      2,247,000 1,733,000 1,803,000 1,657,000 1,510,729 1,229,318 1,194,659 1,148,006 1,075,049 1,061,791 943,071 922,220 922,647 1,029,600 1,025,521 1,025,521 1,017,262 1,007,127 989,989 972,386 944,089 828,379 773,990 764,258 763,135 757,060 746,613 741,771 739,516 708,382 655,098 623,782 592,941 582,136 553,600 542,775 534,828 531,874 530,649 319,224 319,224 319,224 256,069 210,558 183,887 177,827 
  subtotal                      4,434,000 3,594,000 3,791,000 3,647,000 3,501,168 3,207,208 3,171,420 3,114,963 3,040,636 3,027,378 2,894,775 2,857,623 2,884,872 2,967,032 2,894,615 2,867,678 2,837,521 2,805,674 2,774,793 2,733,665 2,391,142 2,283,900 2,204,978 2,186,201 2,184,640 2,175,254 1,983,468 1,949,531 1,969,674 1,818,246 846,181 800,795 767,107 756,302 726,506 713,031 701,071 698,117 693,772 686,458 686,458 686,242 579,032 315,976 280,349 263,214 
  less: accumulated depreciation                      -2,298,000 -2,276,000 -2,424,000 -2,328,000 -2,234,286 -2,163,430 -2,084,769 -2,008,927 -1,930,140 -1,846,496 -1,759,794 -1,670,245 -1,585,914 -1,605,173 -1,513,071 -1,421,279 -1,333,608 -1,246,787 -1,161,706 -1,078,060 -1,006,048 -984,882 -924,663 -862,157  -733,347 -673,782 -615,085 -555,459 -501,767 -472,780 -447,393   -375,203 -352,331           
  net property and equipment                      2,136,000 1,318,000 1,367,000 1,319,000 1,266,882 1,043,778 1,086,651 1,106,036 1,110,496 1,180,882 1,134,981 1,187,378 1,298,958 1,361,859 1,381,544 1,446,399 1,503,913 1,558,887 1,613,087 1,655,605 1,385,094 1,299,018 1,280,315 1,324,044 1,386,305 1,441,907 1,309,686 1,334,446 1,414,215 1,316,479 373,401 353,402 344,003 357,778 351,303 360,700 370,846 389,774 408,512 405,422 432,234 457,804 379,244 134,394 105,817 111,479 
  long-term deposits                      36,000 136,000 36,000 36,000   36,166 36,166                                       
  accrued compensation                      1,576,000 963,000 630,000 998,000 712,615 517,692 392,248 491,432 368,321 286,063 248,023 175,829 408,004 523,694 463,558 419,766 372,426 326,928 272,923 535,029 373,417 314,957 208,127 503,194 224,625 218,405 288,337 363,101 136,322 97,351 75,605 86,563 85,261 87,689 85,910 95,619 102,108 103,987 105,671 92,588       
  lease liability - operating, current portion                      771,000 665,000 651,000                                            
  lease liability – financing, current portion                      14,000 14,000 14,000                                            
  deferred rent, current portion                         130,000   130,216 130,216   130,216 130,216    130,216                               
  contingent consideration - current                      371,000 371,000                                             
  deferred rent, long-term                         349,000 386,113 422,828 457,518 492,207 526,365 559,532                                     
  long-term lease liability - operating                      753,000 806,000 980,000                                            
  long-term lease liability - financing                      6,000 10,000 13,000                                            
  contingent consideration – long-term                      1,560,000 1,560,000                                             
  accounts receivable, trade, net of allowance for doubtful accounts of 26 and 0 at june 30, 2019 and december 31, 2018, respectively                       3,832,000                                             
  investment in savsu                       6,100,000 6,317,000 6,548,000 6,856,980 1,899,669 926,364 1,070,120 1,367,792 1,585,527 1,845,632 2,075,000                                   
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at march 31, 2019 and december 31, 2018                        2,927,000                                            
  accounts receivable, trade, net of allowance for doubtful accounts of 0 and 6 at december 31, 2018 and 2017, respectively                         3,045,000                                           
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 0 and 4,250 shares issued and outstanding at december 31, 2018 and 2017, respectively                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 0 and 5,575 at september 30, 2018 and december 31, 2017, respectively                          2,699,342                                          
  long term deposits                          36,166 36,166   36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166 36,166    
  deferred rent                          130,216 130,216   130,216 130,216   130,216 130,216 130,216  130,216 130,216 130,216 130,216 110,284 117,501 117,501 111,250 111,250 111,250 111,250 111,250 97,880 87,234                 
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 3,187 and 4,250 shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively                                                                   
  accounts receivable, trade, net of allowance for doubtful accounts of 0 and 5,575 at june 30, 2018 and december 31, 2017, respectively                           2,166,415                                         
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 3,187 and 4,250 shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively                                                                   
  accounts receivable, trade, net of allowance for doubtful accounts of 5,575 at march 31, 2018 and december 31, 2017                            1,043,815                                        
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 4,250 shares issued and outstanding at march 31, 2018 and december 31, 2017                                                                   
  accounts receivable, trade, net of allowance for doubtful accounts of 5,575 and 0 at december 31, 2017 and 2016, respectively                             1,021,315                                       
  promissory note payable to related party, net of discount of 155,996 at december 31, 2016                                 2,844,004                                   
  accrued interest, related party                               33,274 181,190 97,857 39,524 8,333                                 
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 4,250 and 0 shares issued and outstanding at december 31, 2017 and 2016, respectively                                                                   
  total biolife solutions, inc. shareholders’ equity                             10,092,586      6,822,439 7,442,610                                
  accounts receivable, trade, net of allowance for doubtful accounts of 6,575 and 0 at september 30, 2017 and december 31, 2016, respectively                              1,355,115                                      
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 4,250 and 0 shares issued and outstanding at september 30, 2017 and december 31, 2016, respectively                                                                   
  accounts receivable, trade, net of allowance for doubtful accounts of 8,913 and 0 at june 30, 2017 and december 31, 2016, respectively                               1,173,036                                     
  preferred stock, 0.001 par value; 1,000,000 shares authorized, series a, 4,250 shares designated, and 4,250 and 0 shares issued and outstanding at june 30, 2017 and december 31, 2016, respectively                                                                   
  accounts receivable, trade, net of allowance for doubtful accounts of 15,798 and 0 at march 31, 2017 and december 31, 2016                                1,060,773                                    
  promissory note payable to related party, net of discount of 62,398 and 155,996 at march 31, 2017 and december 31, 2016                                3,937,602                                    
  deferred rent, long term                                590,716 685,450 713,751 740,888 766,044 784,458 809,275 832,976 848,041 874,825 753,842 795,145 840,730 891,986 918,307 942,955 798,084 838,829 714,391 697,878                 
  short term investments                                     1,651,341 2,902,105 2,956,428 5,606,453 7,399,636 7,744,285 6,012,309                         
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at december 31, 2016 and 2015                                 1,193,646                                   
  internal use software                                  2,250,638 2,021,489 1,836,220 1,698,735 1,187,022 762,860 334,640                            
  intangible asset                                  2,215,385 2,215,385 2,215,385 2,215,385 2,215,385 2,215,385 2,215,385 2,215,385                           
  shareholders' equity                                                                    
  total biolife solutions, inc. shareholders' equity                                 3,166,140 6,161,527   8,508,471 9,151,891 10,021,514 10,836,437 11,803,977                           
  total non-controlling interest equity                                  426,612 723,586 1,087,215 1,350,900 1,632,510 1,855,541 2,011,557 2,132,340                           
  total shareholders' equity                                 3,166,140 6,588,139   9,859,371 10,784,401 11,877,055 12,847,994 13,936,317 12,667,207 13,398,416 14,077,149 -13,271,521  -12,662,694 -12,400,359 -12,486,023 -12,035,782 -11,740,688 -11,430,675 -11,180,486   -10,100,405 -9,548,912    -7,826,982       
  total liabilities and shareholders' equity                                 7,926,614 10,766,378   12,369,622 13,225,577 13,870,187 15,160,420 16,072,918 14,254,063 14,806,565 15,981,534 3,353,342 3,207,024 3,437,081 3,419,277 3,169,829 3,417,833 3,068,907 1,869,170 1,662,017   1,386,251 1,309,059    1,333,958       
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at september 30, 2016 and december 31, 2015                                  1,311,006                                  
  note payable, related party, net of discount of 249,593 at september 30, 2016                                  1,750,407                                  
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at june 30, 2016 and december 31, 2015                                   1,284,015                                 
  note payable, related party, net of discount of 343,191 at june 30, 2016                                   656,809                                 
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at march 31, 2016 and december 31, 2015                                    1,190,260                                
  long term liabilities                                                                    
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at december 31, 2015 and 2014                                     929,289                               
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at september 30, 2015 and december 31, 2014                                      792,274                              
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at june 30, 2015 and december 31, 2014                                       809,387                             
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at march 31, 2015 and december 31, 2014                                        851,044                            
  accounts receivable, trade, net of allowance for doubtful accounts of 0 at december 31, 2014 and 1,100 at december 31, 2013                                         901,623                           
  deferred financing costs                                             114,874 129,136 143,399 157,506 171,458 189,855 208,251 84,997 112,042 139,384 70,466 81,896 97,220           
  promissory notes payable, related parties                                             10,603,127 10,603,127 10,603,127 10,603,127 10,603,127 10,603,127 10,603,127 10,303,127 10,128,127 9,903,127 9,653,127 9,383,127 9,033,127 8,738,127 8,488,127 8,138,127 7,888,127 7,588,127 6,963,127 6,463,127 4,463,127 3,963,127 3,463,127 
  accrued interest, related parties                                             3,501,610 3,316,055 3,130,501 2,944,946 2,759,391 2,573,836 2,388,281 2,204,738 2,025,961 1,852,433 1,680,756 1,515,517 1,354,975 1,199,601 1,049,038 903,346 766,973 632,372 504,080 385,814 193,778   
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at september 30, 2014 and december 31, 2013                                          775,076                          
  deferred revenue                                          90,000       20,000 20,000 178,717 20,000 20,000 20,000 20,000 20,000 20,000 20,000 20,000 20,000 20,000 25,833 8,334 19,166 109,583  7,083 
  accumulated other comprehensive                                          -6,606                          
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at june 30, 2014 and december 31, 2013                                           566,540                         
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2014 and december 31, 2013                                            1,325,564                        
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at december 31, 2013 and 2012                                             1,009,316                       
  deferred revenue, long term                                                 89,167 94,167 99,167 104,167 109,167 114,167 119,167 124,167 129,167 134,167 139,167 144,167 149,167 154,167 67,500 70,000    
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at september 30, 2013 and december 31, 2012                                              1,026,858                      
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at june 30, 2013 and december 31, 2012                                               980,974                     
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2013 and december 31, 2012                                                976,157                    
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at december 31, 2012 and 2011                                                 600,153                   
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at september 30, 2012 and december 31, 2011                                                  797,943                  
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at june 30, 2012 and december 31, 2011                                                   359,190                 
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2012 and december 31, 2011                                                    471,816                
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at december 31, 2011 and 2010                                                     547,143               
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at both september 30, 2011 and december 31, 2010                                                                    
  less: accumulated depreciation and amortization                                                      -423,104 -398,524   -330,225 -308,343 -285,260 -281,036 -254,224 -228,438 -199,788 -181,582 -174,532 -151,735 
  liabilities and stockholders’ equity                                                                    
  accrued expenses                                                      100,445 48,022   88,867 57,841 70,630 51,251 196,284 222,425 203,929 265,879 144,950 150,208 
  stockholders' equity                                                                    
  total stockholders' equity                                                      -10,821,499 -10,483,843   -9,218,113 -8,816,680 -8,322,150  -7,498,600 -6,962,293 -5,982,886 -4,384,400 -3,738,318 -3,089,522 
  total liabilities and stockholders' equity                                                      1,564,376 1,471,981   1,293,655 1,384,760 1,328,018  1,310,008 1,203,450 1,745,300 1,302,592 850,725 854,527 
  accounts receivable, trade, net of allowance for doubtful accounts                                                                    
  of 1,100 at june 30, 2011 and december 31, 2010, respectively                                                       395,324             
  authorized, 69,679,854 issued and outstanding at june 30, 2011 and december 31, 2010                                                       69,680             
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2011 and december 31, 2010, respectively                                                        356,701            
  accounts receivable, trade, net of allowance for doubtful accounts of 1,100 and 550 at december 31, 2010 and 2009, respectively                                                         338,899           
  of 7,400 and 550 at september 30, 2010 and december 31, 2009, respectively                                                          317,058          
  authorized, 69,679,854 issued and outstanding                                                                    
  at september 30, 2010 and december 31, 2009                                                          69,680          
  of 39,900 and 550 at june 30, 2010 and december 31, 2009, respectively                                                           285,241         
  authorized, 69,679,854 issued and outstanding at june 30, 2010 and december 31, 2009                                                           69,680         
  of 20,600 and 550 at march 31, 2010 and december 31, 2009, respectively                                                            358,772        
  authorized, 69,679,854 issued and outstanding at march 31, 2010 and december 31, 2009                                                            69,680        
  accounts receivable, trade, net of allowance for doubtful accounts of 550 and 29,000 at december 31, 2009 and 2008, respectively                                                             315,365       
  accounts receivable, trade, net of allowance for doubtful accounts of 5,000 and 29,000 at september 30, 2009 and december 31, 2008, respectively                                                              369,329      
  accounts receivable, trade, net of allowance for doubtful accounts of 9,000 and 29,000 at june 30, 2009 and december 31, 2008, respectively                                                               199,192     
  accounts receivable, trade, net of allowance for doubtful accounts of 12,000 and 29,000 at march 31, 2009 and december 31, 2008, respectively                                                                244,963    
  other receivable                                                                79,904    
  modular clean room                                                                202,270    
  accounts receivable, trade, net of allowance for doubtful accounts of 5,000 at both september 30, 2008 and december 31, 2007                                                                 362,145   
  prepaid expenses                                                                 133,257 292,440 285,068 
  shares authorized, 69,639,854 and 69,606,520 shares issued and outstanding at september 30, 2008 and december 31, 2007, respectively                                                                 69,640   
  accounts receivable, trade, net of allowance for doubtful accounts of 3,000 and 5,000 at june 30, 2008 and december 31, 2007, respectively                                                                  228,931  
  other current assets                                                                  14,167 10,000 
  of 3,000 and 5,000 at march 31, 2008 and december 31, 2007, respectively                                                                   214,751 
  shares authorized, 69,639,854 and 69,606,520 shares issued and outstanding at march 31, 2008 and december 31, 2007                                                                   69,640 

We provide you with 20 years of balance sheets for BioLife Solutions stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BioLife Solutions. Explore the full financial landscape of BioLife Solutions stock with our expertly curated balance sheets.

The information provided in this report about BioLife Solutions stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.